The price-to-earnings ratio for Pfizer Inc. (NYSE: PFE) is above average at 74.18x. The 36-month beta value for PFE is also noteworthy at 0.61. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 1 rating it as “overweight,” 9 rating it as “hold,” and 0 rating it as “sell.”
The public float for PFE is 5.64B, and at present, short sellers hold a 1.27% of that float. The average trading volume of PFE on April 08, 2024 was 42.99M shares.
PFE) stock’s latest price update
Pfizer Inc. (NYSE: PFE)’s stock price has plunge by 0.04relation to previous closing price of 26.65. Nevertheless, the company has seen a -3.93% plunge in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-05 that With the market off to a rather wobbly start to the second quarter of 2024, investors may be looking for the most undervalued biotech stocks to buy in April that can offer more bang for one’s buck. For new investors seeking reasonable valuations and overlooked long-term growth drivers, the biotech scene is worth considering.
PFE’s Market Performance
PFE’s stock has fallen by -3.93% in the past week, with a monthly drop of -1.95% and a quarterly drop of -8.35%. The volatility ratio for the week is 1.70% while the volatility levels for the last 30 days are 1.78% for Pfizer Inc. The simple moving average for the last 20 days is -3.48% for PFE stock, with a simple moving average of -14.98% for the last 200 days.
Analysts’ Opinion of PFE
Guggenheim, on the other hand, stated in their research note that they expect to see PFE reach a price target of $36. The rating they have provided for PFE stocks is “Buy” according to the report published on February 23rd, 2024.
TD Cowen gave a rating of “Market Perform” to PFE, setting the target price at $32 in the report published on January 04th of the current year.
PFE Trading at -2.64% from the 50-Day Moving Average
After a stumble in the market that brought PFE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.85% of loss for the given period.
Volatility was left at 1.78%, however, over the last 30 days, the volatility rate increased by 1.70%, as shares sank -0.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.89% lower at present.
During the last 5 trading sessions, PFE fell by -3.93%, which changed the moving average for the period of 200-days by -32.23% in comparison to the 20-day moving average, which settled at $27.62. In addition, Pfizer Inc. saw -7.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PFE starting from Gottlieb Scott, who purchase 3,000 shares at the price of $26.47 back on Dec 15 ’23. After this action, Gottlieb Scott now owns 9,000 shares of Pfizer Inc., valued at $79,401 using the latest closing price.
Gottlieb Scott, the Director of Pfizer Inc., purchase 1,000 shares at $38.58 during a trade that took place back on May 08 ’23, which means that Gottlieb Scott is holding 6,000 shares at $38,580 based on the most recent closing price.
Stock Fundamentals for PFE
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.49 for the gross margin
The net margin for Pfizer Inc. stands at 0.04. The total capital return value is set at 0.02. Equity return is now at value 2.31, with 1.01 for asset returns.
Based on Pfizer Inc. (PFE), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at 0.12. The debt to equity ratio resting at 0.81. The interest coverage ratio of the stock is 1.63.
Currently, EBITDA for the company is 10.53 billion with net debt to EBITDA at 7.3. When we switch over and look at the enterprise to sales, we see a ratio of 3.81. The receivables turnover for the company is 5.23for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.91.
Conclusion
In summary, Pfizer Inc. (PFE) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
